

Table 14.3.3.1a
Summary of Observed and Change from Baseline by Scheduled Visits - Vital Signs
Safety Population

Parameter (Units)	Visit	Placebo (N=XX)	Xanomeline		Xanomeline		
		Observed	Change from Baseline	Low Dose (N=XX)	High Dose (N=XX)	Observed	Change from Baseline
<Parameter 1>							
<unit>							
Baseline							
n		XX		XX		XX	
Mean (SD)		XX.X (XX.XX)		XX.X (XX.XX)		XX.X (XX.XX)	
Median		XX.X		XX.X		XX.X	
Q1, Q3		XX.X, XX.X		XX.X, XX.X		XX.X, XX.X	
Min, Max		XX, XX		XX, XX		XX, XX	
...							
<Visit n>							
n		XX	XX	XX	XX	XX	
Mean (SD)		XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)	
Median		XX.X	XX.X	XX.X	XX.X	XX.X	
Q1, Q3		XX.X, XX.X	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X	
Min, Max		XX, XX	XX, XX	XX, XX	XX, XX	XX, XX	
<Parameter n>							
<unit>							
...							

Note: Baseline is defined as the last assessment that is non-missing prior to first dose of investigational product.

Source dataset: advs, Generated on: DDMONYYYY:HH:MM

Program: <pid>.sas, Output: <pid><oid>.rtf, Generated on: DDMONYYYY:HH:MM